Human CD300a/LMIR1 Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB2640

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
MAB2640
MAB2640-SP
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Human

Applications

CyTOF-ready, Flow Cytometry, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Rat IgG2A Clone # 232612

View all CD300a/LMIR1 Antibodies »

Product Specifications

Immunogen

Y3 rat myeloid cell line transfected with human CD300a/LMIR1

Specificity

Detects human CD300a/LMIR1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, 100% cross‑reactivity with recombinant human LMIR2 (CMRF-35A) is observed and no cross-reactivity with recombinant human LMIR3, 4, 5, or 6 is observed.

Clonality

Monoclonal

Host

Rat

Isotype

IgG2A

Scientific Data Images for Human CD300a/LMIR1 Antibody

Detection of Human CD300a/LMIR1 antibody by Western Blot.

Detection of Human CD300a/LMIR1 by Western Blot.

Western blot shows lysates of human granulocytes. PVDF membrane was probed with 2 µg/mL of Rat Anti-Human CD300a/LMIR1 Monoclonal Antibody (Catalog # MAB2640) followed by HRP-conjugated Anti-Rat IgG Secondary Antibody (HAF005). A specific band was detected for CD300a/LMIR1 at approximately 60 kDa (as indicated). This experiment was conducted under non-reducing conditions and using Immunoblot Buffer Group 1.

Applications for Human CD300a/LMIR1 Antibody

Application
Recommended Usage

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry

2.5 µg/106 cells
Sample: Human whole blood

Western Blot

Human granulocytes under non-reducing conditions only

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CD300a/LMIR1

CD300a, also known as LMIR1 (in rodents), CMRF-35H, IRp60, CLM-8, and MAIR-I, is a 60 kDa glycoprotein member of the immunoglobulin superfamily (1). Human CD300a consists of a 163 amino acid (aa) extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane segment, and a 98 aa cytoplasmic domain that contains three immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and a non-canonical ITIM (2). Alternative splicing may generate additional isoforms that either lack the Ig-like domain or contain only the cytoplasmic domain. Within the ECD, human CD300a shares 40% and 43% aa sequence identity with mouse and rat LMIR1, respectively. In human, CD300a is expressed on peripheral blood eosinophils, mast cells, neutrophils, plasmacytoid dendritic cells, and various T cell subsets (3‑7). Antibody crosslinking of CD300a induces phosphorylation of tyrosine residues in the cytoplasmic domain. This leads to the recruitment of phosphatases SHIP, SHP-1, and SHP-2 and inhibition of NK cell, eosinophil, and mast cell activation (2, 3, 5‑7). Crosslinking of CD300a to other surface proteins such as SCF R or Fc epsilon RI on mast cells, Fc gamma RIIA on neutrophils, or CCR3 on mast cells and eosinophils inhibits downstream signaling from those receptors (5, 10‑12). CD300a crosslinking also limits the in vivo activities of these cells with a subsequent reduction of allergic inflammation symptoms (4, 11, 12).

References

  1. Clark, G.J. et al. (2009) Trends Immunol. 30:209.
  2. Cantoni, C. et al. (1999) Eur. J. Immunol. 29:3148.
  3. Munitz, A. et al. (2006) Blood 107:1996.
  4. Bachelet, I. et al. (2005) J. Immunol. 175:7989.
  5. Alvarez, Y. et al. (2008) Mol. Immunol. 45:253.
  6. Ju, X. et al. (2008) Blood 112:1184.
  7. Clark, G.J. et al. (2007) J. Leukoc. Biol. 82:1126.
  8. Kumagai, H. et al. (2003) Biochem. Biophys. Res. Commun. 307:719.
  9. Yotsumoto, K. et al. (2003) J. Exp. Med. 198:223.
  10. Bachelet, I. et al. (2008) J. Immunol. 180:6064.
  11. Bachelet, I. et al. (2006) J. Allergy Clin. Immunol. 117:1314.
  12. Munitz, A. et al. (2006) J. Allergy Clin. Immunol. 118:1082.

Alternate Names

CD300a, CLM8, CMRF-35H, IGSF12, IRC1, IRC2, IRp60, LMIR1, MAIR-I, Mcipr1, NKRL, Pigr4

Entrez Gene IDs

11314 (Human); 217303 (Mouse)

Gene Symbol

CD300A

Additional CD300a/LMIR1 Products

Product Documents for Human CD300a/LMIR1 Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human CD300a/LMIR1 Antibody

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.